|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
|
|
4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS
|
|
|
|
4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
|
|
|
Immunotherapy Screening Using Immune-Enhanced Organoids [GEN]
|
|
|
|
|
|
For this study, the researchers were able to combine melanoma cells and white blood cells from the patients’ peripheral blood and lymph nodes and create patient-specific, immune-active tumor organoids to test their response to immunotherapy treatment.
|
|
|
|
|
|
|
5.12.13 IMMUNOTHÉRAPIES - BIOMARQUEURS
|
|
|
|
5.12.3 IMMUNOTHÉRAPIES-COMBINAISONS
|
|
|
|
5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH
|
|
|
|
|
|
5.17 TRAITEMENTS - RADIOTHÉRAPIE
|
|
|
|
5.2.6 PHARMA - BIOTECH
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA,...
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
5.4.1 TRAITEMENTS - ECONOMIE - NICE
|
|
|
NICE shuts out AstraZeneca's Tagrisso—and dings J&J's Stelara, too [Fierce Pharma]
|
|
|
|
|
|
The treatment has won global approvals on the back of data showing it could stall cancer growth for 18.9 months, compared with 10.2 months for rival meds Tarceva from Roche and Iressa from AZ. But there’s no direct evidence that it works better than Gilotrif, a med the National Institute for Health and Care Excellence (NICE) already backs.
|
|
|
|
|
|
|
NICE stays sour on AstraZeneca's Tagrisso [EndPoints]
|
|
|
|
|
|
Tagrisso, which was AstraZeneca’s top-selling treatment in the first nine months of 2019, carries a list price of £5,770 for 80 mg and 40 mg. The company has a commercial arrangement (i.e. a discount), which would have applied if the drug had been recommended.
|
|
|
|
|
|
|
6. LUTTE CONTRE LES CANCERS
|
|
|
Supporting adult carers [NICE]
|
|
|
|
|
|
This guideline covers support for adults (aged 18 and over) who provide unpaid care for anyone aged 16 or over with health or social care needs. It aims to improve the lives of carers by helping health and social care practitioners identify people who are caring for someone and give them the right information and support.
|
|
|
|
|
|
|
|
6.3 ASSOCIATIONS/FONDATIONS
|
|
|
|
6.6 PUBLICATIONS, POLITIQUES SCIENTIFIQUES
|
|
|
|
|
6.7.3 DMP
|
|
|